Lyell Immunopharma, Inc.
LYEL
$17.92
-$1.10-5.78%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -45.45% | -55.88% | -38.46% | 133.33% | -15.38% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -45.45% | -55.88% | -38.46% | 133.33% | -15.38% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -45.45% | -55.88% | -38.46% | 133.33% | -15.38% |
| SG&A Expenses | -26.90% | -9.19% | -20.15% | 4.09% | 10.29% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 7.38% | -117.95% | -37.09% | -27.60% | -33.30% |
| Total Operating Expenses | -0.44% | -26.26% | -15.98% | 0.94% | 4.52% |
| Operating Income | 0.43% | 26.24% | 15.97% | -0.93% | -4.52% |
| Income Before Tax | 26.68% | 12.87% | 6.82% | 13.96% | -262.62% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 26.68% | 12.87% | 6.82% | 13.96% | -262.62% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 26.68% | 12.87% | 6.82% | 13.96% | -262.62% |
| EBIT | 0.43% | 26.24% | 15.97% | -0.93% | -4.52% |
| EBITDA | -4.17% | 24.31% | 13.87% | -4.15% | -5.00% |
| EPS Basic | 49.98% | 38.88% | 19.56% | 25.87% | -227.44% |
| Normalized Basic EPS | 7.63% | 38.88% | 26.81% | 10.88% | 3.09% |
| EPS Diluted | 49.98% | 38.88% | 19.56% | 25.87% | -227.44% |
| Normalized Diluted EPS | 7.63% | 38.88% | 26.81% | 10.88% | 3.09% |
| Average Basic Shares Outstanding | 46.56% | 42.55% | 15.84% | 16.07% | 10.74% |
| Average Diluted Shares Outstanding | 46.56% | 42.55% | 15.84% | 16.07% | 10.74% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |